Somewhat surprising outcome, IMO, and possibly a Pyrrhic victory insofar as Bayer will have a hard time getting individual EU countries to reimburse Xarelto for the ACS indication.
Xarelto® (rivaroxaban) has been approved by the European Commission for the prevention of atherothrombotic events (cardiovascular death, myocardial infarction or stroke) after an Acute Coronary Syndrome (ACS)
News 
Market Data 
Discover 
